Altimmune (NASDAQ: ALT) Posts Q2 2026 Results With $519M Cash as Pemvidutide Advances Across Three Liver Disease Trials

Altimmune (NASDAQ: ALT) reported a Q2 2026 GAAP net loss of $22.8 million, or $0.12 per share, beating the $0.14 consensus estimate by $0.02, while simultaneously announcing three clinical milestones for its lead drug candidate pemvidutide across metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company held $519 million in cash, cash equivalents, and investments as of June 30, 2026.

Q2 2026 Financial Results

• GAAP EPS of -$0.12 beat the consensus estimate of -$0.14; the prior-year quarter posted a GAAP EPS of -$0.27, reflecting the impact of a significantly higher share count following the April 2026 equity offering
• Net loss of $22.8 million compared to $22.1 million in Q2 2025, a 3.1% increase year-over-year
• R&D expenses of $18.7 million, up 8.2% from $17.2 million in Q2 2025, with $11.6 million in direct pemvidutide development costs; the increase reflects ALD trial activity and PERFORMA Phase 3 startup costs
• G&A expenses of $7.6 million, up 33.1% from $5.7 million in Q2 2025, driven by higher professional services and compensation
• Interest income of $4.5 million for the quarter, supported by the company's investment portfolio

What Drove the Results

Altimmune's GAAP EPS of -$0.12 beat the -$0.14 consensus by $0.02. The company generates no product revenue and remains fully funded through its investment portfolio. The operating loss widened to $26.2 million from $22.9 million year-over-year, primarily because G&A costs rose 33.1% on higher professional services and compensation, while R&D spending increased modestly as PERFORMA Phase 3 startup costs and the ongoing RESTORE ALD trial more than offset the wind-down of IMPACT Phase 2b expenses.

The April 2026 equity offering, which raised $225.0 million in gross proceeds and was oversubscribed, meaningfully increased the share count from approximately 81.5 million weighted-average shares in Q2 2025 to 185.4 million in Q2 2026. This dilution is the primary reason the per-share loss improved to -$0.12 from -$0.27 despite a slightly larger absolute net loss.

Why It Matters

The quarter's clinical news carried equal weight alongside the financial results. In August 2026, Altimmune initiated the global PERFORMA Phase 3 trial, a randomized, double-blind, placebo-controlled study of pemvidutide in MASH patients, with a 52-week data readout anticipated in 2029. Pemvidutide already holds FDA Breakthrough Therapy Designation for MASH based on 24-week data from the IMPACT Phase 2b trial.

In July 2026, the company reported positive topline results from the RECLAIM Phase 2 trial in AUD, in which pemvidutide met the primary endpoint of statistically significant reduction in heavy drinking days across 100 patients over 24 weeks. Key secondary endpoints, including a two-level reduction in WHO-risk drinking levels and zero heavy drinking days, were also met. The FDA has granted Fast Track designation to pemvidutide for AUD. Separately, patient enrollment in the RESTORE Phase 2 ALD trial was completed in July 2026, with topline data expected in the second half of 2027.

Wall Street View

Altimmune's analyst consensus as of August 1, 2026 skewed constructive, with the composition of ratings shifting modestly more positive compared to the prior month. With $519 million in cash on hand and a term loan of $34.7 million, the company's runway positions it to execute on all three ongoing clinical programs without near-term financing pressure.

Investor Takeaway

The Q2 results confirm Altimmune is executing its clinical strategy across three indications simultaneously, a capital-intensive approach now supported by a reinforced balance sheet. The RECLAIM AUD data represent the first Phase 2 readout to demonstrate pemvidutide's efficacy beyond liver-focused endpoints, broadening the drug's potential commercial profile if Phase 3 proceeds. With no product revenue expected before a potential MASH approval and the PERFORMA data readout not until 2029, investors are effectively pricing the $519 million cash reserve and the probability of pemvidutide's regulatory success across all three programs.